Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPRINTEC vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium to prevent pregnancy.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 15 years of age who have achieved menarche and are seeking an oral contraceptive
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (0.25 mg norgestimate, 0.035 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Ethinyl estradiol: 13 ± 3 hours (variable, influenced by CYP3A4 activity); Norgestimate: 1.5-2 hours (rapidly converted to norelgestromin); Norelgestromin: 12-20 hours (active metabolite); clinical context: dosing interval of 24 hours supports once-daily administration.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol is metabolized primarily by CYP3A4; norgestimate is rapidly metabolized to norelgestromin and norgestrel via first-pass metabolism.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: approximately 50-60% (metabolites, primarily glucuronide conjugates), Fecal: approximately 30-40% (biliary excretion of metabolites), with minimal unchanged drug in urine (<5%).
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinyl estradiol: >97% bound to albumin; Norgestimate/norelgestromin: 99% bound to albumin and sex hormone-binding globulin (SHBG).
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinyl estradiol: 2.5-4.0 L/kg; Norgestimate: not determined (extensive tissue distribution); clinical meaning: reflects distribution into total body water and tissues.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Ethinyl estradiol: 38-48% due to first-pass metabolism; Norgestimate: 100% (prodrug, rapidly hydrolyzed in gut wall and liver).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use caution.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). No data for mild impairment; use with caution.
No data available for fictional drug ALYACEN 777.
Safety and efficacy have not been established in postmenarchal pediatric patients. Use after first menses; dosing same as adults.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women. No specific dose adjustment needed for elderly patients beyond contraindications.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptive use. Risk increases with age (>35 years) and number of cigarettes smoked. Women over 35 who smoke should not use combined oral contraceptives.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders,Increased risk of myocardial infarction and stroke, especially in smokers,Increased risk of hepatic neoplasia,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
Avoid grapefruit juice as it may increase estrogen levels and risk of adverse effects. No other significant food interactions are known; maintain consistent dietary habits to minimize gastrointestinal side effects.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular and limb defects; increased risk of neural tube defects. Second and third trimesters: Fetal genital abnormalities in females (diethylstilbestrol-like effect); potential for long-term reproductive tract changes. Postnatal: Possible increased risk of neurodevelopmental issues.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in human breast milk with milk-to-plasma ratio approximately 0.5. Potential adverse effects in nursing infant including jaundice and breast enlargement. Use during lactation not recommended unless clearly necessary. May reduce milk production and quality.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustments approved; contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) could reduce efficacy if used, but use is contraindicated.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
SPRINTEC (ethinyl estradiol/norgestimate) is a combined oral contraceptive. Prescribe with caution in women with migraine with aura due to increased stroke risk. If a dose is missed, take as soon as remembered; if >24 hours late, use backup contraception for 7 days. Monitor blood pressure at initiation and annually. Discontinue if pregnancy is suspected or confirmed. Advise that antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time each day, in the order directed on the pill pack.,If you miss a pill, refer to the package insert or consult your healthcare provider; use backup contraception as directed.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding; these often improve within a few cycles.,Seek immediate medical attention for symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,Inform your provider about all medications, including over-the-counter drugs and herbal supplements, especially St. John's Wort.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPRINTEC vs ALYACEN 777, answered by our medical review team.
SPRINTEC is a Oral Contraceptive that works by Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium to prevent pregnancy.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPRINTEC and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPRINTEC is: One tablet (0.25 mg norgestimate, 0.035 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPRINTEC and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPRINTEC is classified as Category C. FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular and limb defects; increased risk of neural tube def. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.